• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » ECT in Severe Adolescent Mood ­Disorders

ECT in Severe Adolescent Mood ­Disorders

May 20, 2021
John Raiss, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
John Raiss, MD. Dr. Raiss has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Ghaziuddin N et al, J Child Adolesc Psychopharmacol 2020;30(4):235–243

ECT is the gold standard for treatment of severe unipolar depression in adults, with remission rates of 70%–90% in randomized trials. In bipolar depression, response rates are 50%–75%. A 2020 retrospective chart study reviewed ECT’s utility in adolescents with severe mood disorders.

The study consisted of 54 adolescents, mean age 15.8, with treatment-resistant mood disorders (two-thirds unipolar, one-third bipolar), who received ECT at the University of Michigan Medical Center from 1996 to 2010. Treatment resistance was defined as failure to respond to 3 or more mood-stabilizing medications combined with psychotherapy. The patients averaged 4 hospitalizations, 2 suicide attempts, and 7 failed medication trials (4 antidepressants, 3 antipsychotics and mood stabilizers), each of at least 6 weeks duration, with adequate dosage and good compliance.

The patients received a mean of 13.7 ECT treatments, almost all with bilateral electrode placement. The primary outcome measure was Clinical Global Impressions (CGI) score; response was defined as a CGI score of 2 (much improved), while remission was defined as a score of 1 (very much improved).

The response rate at the end of the index ECT treatment was 52.8%, while the remission rate was 15%, both lower than typical findings in adults. While rates increased at 6 and 12 months, this improvement occurred only with observed cases (OC) data, and with dropouts removed. There was minimal improvement at later time points when looking at last observation carried forward (LOCF) data. There was no difference in response or remission rates between unipolar and bipolar patient groups. Still, by the end of index treatment, suicidal ideation declined from roughly 80% to 40%; self-injurious behavior declined from about 50% to 18%; and school attendance increased threefold, from 20% to 60%. Side effects were minimal.

The limitations of this study included its relatively small size for a chart review, the use of non-blinded raters, the use of the CGI as the measure of treatment outcome (due to missing depression rating scale data), obtaining data from retrospective chart review, and diagnoses made without the use of standardized instruments.

CCPR’s Take
While ECT in adolescents appears less effective than in adults, it did produce clinically meaningful changes in these treatment-resistant patients for a year after the index ECT course. Keep it in mind as a possible tool.
Child Psychiatry
KEYWORDS children-and-adolescents electroconvulsive-therapy research-update
    John Raiss, MD.

    SSRIs vs SNRIs in Pediatric Anxiety Disorders: Which Are More Tolerable?

    More from this author
    www.thecarlatreport.com
    Issue Date: May 20, 2021
    SUBSCRIBE NOW
    Table Of Contents
    Welcome to the 21st Century Cures Act Information Sharing Rules
    ECT in Severe Adolescent Mood ­Disorders
    The Effect of Age and Pubertal Stage on Mental Health in Gender-Incongruent Youths
    Note From the Editor-in-Chief
    Approaches to Autism Intervention
    Effect Size Matters: The Seismic Shift Toward Naturalistic and Developmental Interventions in Autism
    Viloxazine (Qelbree): A Faster Strattera?
    Pharmacotherapy for Autism Spectrum Disorder
    CME Post-Test - Autism in Children and Adolescents, CCPR, April/May/June 2021
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2432683359.jpg
      Child Psychiatry

      Hidden Dangers: The Fentanyl Crisis and Teen Overdose Prevention

      The Fentanyl overdose crisis is now one of the leading causes of death among adolescents, and it is happening in every corner of the country. Stay with us as we talk about the...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.